HK1213924A1 - 用於治療癌症的抗 和抗 抗體組合 - Google Patents

用於治療癌症的抗 和抗 抗體組合

Info

Publication number
HK1213924A1
HK1213924A1 HK16101933.0A HK16101933A HK1213924A1 HK 1213924 A1 HK1213924 A1 HK 1213924A1 HK 16101933 A HK16101933 A HK 16101933A HK 1213924 A1 HK1213924 A1 HK 1213924A1
Authority
HK
Hong Kong
Prior art keywords
kir
ctla
antibodies
combination
treat cancer
Prior art date
Application number
HK16101933.0A
Other languages
English (en)
Inventor
F Graziano Robert
K Gupta Ashok
young kim Su
Wigginton Jon
Andre Pascale
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1213924A1 publication Critical patent/HK1213924A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK16101933.0A 2012-10-23 2016-02-22 用於治療癌症的抗 和抗 抗體組合 HK1213924A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717304P 2012-10-23 2012-10-23
PCT/US2013/066431 WO2014066532A1 (en) 2012-10-23 2013-10-23 Combination of anti-kir and anti-ctla-4 antibodies to treat cancer

Publications (1)

Publication Number Publication Date
HK1213924A1 true HK1213924A1 (zh) 2016-07-15

Family

ID=49519136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101933.0A HK1213924A1 (zh) 2012-10-23 2016-02-22 用於治療癌症的抗 和抗 抗體組合

Country Status (4)

Country Link
US (2) US9789182B2 (zh)
EP (1) EP2912063A1 (zh)
HK (1) HK1213924A1 (zh)
WO (1) WO2014066532A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004253630B2 (en) * 2003-07-02 2010-11-25 Innate Pharma S.A.S. Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies
US9005619B2 (en) 2009-12-07 2015-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for enhancing anti-tumor antibody therapy
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US9810692B2 (en) * 2012-10-26 2017-11-07 Institut Gustave Roussy Methods for predicting the sensitivity of a subject to immunotherapy
WO2015198311A1 (en) * 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and kir for cancer therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
ES2772307T3 (es) * 2014-10-28 2020-07-07 Childrens Univ Hospital Tuebingen Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
EP3281010B1 (en) 2015-04-10 2020-12-30 The Regents of The University of California Methods of determining patient populations amenable to immunomodulatory treatment of cancer
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6944925B2 (ja) 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
GEP20227438B (en) 2015-07-30 2022-11-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
US11072657B2 (en) * 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
WO2017118867A1 (en) 2016-01-08 2017-07-13 Replimune Limited Use of an oncolytic virus for the treatment of cancer
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
GB201604213D0 (en) 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN111670051A (zh) 2017-11-08 2020-09-15 亚飞（上海）生物医药科技有限公司 生物分子偶联物及其用途
WO2019097369A1 (en) 2017-11-14 2019-05-23 Pfizer Inc. Ezh2 inhibitor combination therapies
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2019243847A1 (en) 2018-06-21 2019-12-26 Replimune Limited Treatment using oncolytic virus
EP3825333A4 (en) * 2018-07-06 2022-04-06 Abmax Biopharmaceuticals LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
AU2019345151A1 (en) 2018-09-19 2021-04-29 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
AU2022218137A1 (en) * 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN117203235A (zh) * 2021-04-21 2023-12-08 和铂医药(上海)有限责任公司 结合ctla-4的抗体及其用途
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023076876A1 (en) * 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022377644A1 (en) * 2021-10-29 2024-05-16 OncoC4, Inc. Anti-ctla-4 antibody dosing regimens
WO2024050429A2 (en) * 2022-08-30 2024-03-07 Adagene Pte. Ltd. Methods for treating cancer using anti-ctla4 antibodies
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
CN105682683A (zh) * 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN107109459A (zh) * 2014-11-05 2017-08-29 加利福尼亚大学董事会 用于分层对阻断pd1/pdl1轴的疗法的无响应者的方法

Also Published As

Publication number Publication date
WO2014066532A1 (en) 2014-05-01
US10688180B2 (en) 2020-06-23
EP2912063A1 (en) 2015-09-02
US9789182B2 (en) 2017-10-17
US20180117147A1 (en) 2018-05-03
US20150283234A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
HK1213924A1 (zh) 用於治療癌症的抗 和抗 抗體組合
HK1210786A1 (zh) 抗體和抗 抗體的組合用於治療癌症
IL290295A (en) A combination of antibodies against lag-3 and antibodies against pd-1 for the treatment of tumors
HK1253723A1 (zh) 人單克隆抗-pd-l1抗體和使用方法
HK1210481A1 (zh) 單試劑抗 雙結合抗體以及使用方法
HK1213581A1 (zh) 抗- 抗體及其使用方法
HK1211035A1 (zh) 針對整聯蛋白α 的抗體和使用該抗體治療癌症
HK1212256A1 (zh) 抗- 抗體及相關使用方法
HK1205517A1 (zh) 抗體及使用方法
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
HK1201855A1 (zh) 治療癌症的抗體和方法
EP2700652A4 (en) DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES
HK1213584A1 (zh) 用於治療癌症的 抗體及方法
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment